# Phase 5 Implementation Status

## Current State

- Branch: `phase-5-auth`.
- Phase implemented: `Phase 5 - Authentication and account activity`.
- Risk assumption: HIGH, because auth/JWT/password behavior was touched.

## Completed

- Added Phase 5 auth tests with RED run proving `/api/auth/*` routes were absent.
- Added request-scoped database session dependency.
- Added safe auth schemas for register/login/current-user/token responses.
- Added JWT access-token creation and validation using configured secret, algorithm, and expiry.
- Added current active user dependency that rejects missing, malformed, expired, unknown-user, and inactive-user tokens.
- Added optional authenticated-user dependency for guest-only auth endpoint enforcement.
- Added `POST /api/auth/register`.
- Added `POST /api/auth/login`.
- Added `GET /api/auth/me`.
- Registered auth router under `/api`.
- Skipped optional `POST /api/auth/logout` per plan because client-side token deletion is acceptable and no token invalidation storage is required.
- Updated `backend/index.md` to reflect current backend auth state.

## Quality Gates

- `python -m pytest tests/test_auth.py` from `backend/`: PASS, 16 passed.
- `python -m ruff check .` from `backend/`: PASS.
- `python -m pytest` from `backend/`: PASS, 38 passed.
- Final review-resolution verification:
  - `python -m ruff check .` from `backend/`: PASS.
  - `python -m pytest` from `backend/`: PASS, 38 passed.

## Code Review Resolution

- `.context/review-code-openai.md`: APPROVED with no critical, important, or optional issues.
- `.context/review-code-claude.md`: not present or empty.
- `.context/review-code-resolution.md`: FIXED.
- Source fixes applied during review resolution: none; no accepted source fixes existed.
- Index updates after review resolution: skipped; no files were created, deleted, renamed, or materially changed by accepted fixes.

## Deviations

- No deviations from `.context/design.md`, `.context/plan.md`, or `.context/review-plan-resolution.md`.

## Remaining Risks

- No known Phase 5 blockers.
